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PURPOSE. To establish structure-function correlations across the
visual field, to investigate disease progression in Best macular
dystrophy (BMD), by correlating structural damage with retinal
function as assessed by the combination of psychophysics and
multifocal electrophysiology.
METHODS. Spatial achromatic and chromatic contrast sensitivi-
ties (probing red-green and blue-yellow pathways) were as-
sessed using custom-made psychophysical software to evaluate
retinal damage in BMD and age-matched control eyes (n  19
and n  22, respectively). Neurosensory retinal dysfunction
was also evaluated by means of multifocal electroretinography
(mfERG). Correlation analysis was performed between func-
tional parameters in BMD, clinical measures, and morphologic
data obtained by optical coherence tomography (OCT).
RESULTS. Significant peripheral impairment of retinal function,
as measured by mfERG and spatial achromatic contrast sensi-
tivity (CS) methods, was found in BMD. Furthermore, changes
in thickness of the neurosensory retina, as measured by OCT,
and reduced mfERG responses were also indicators of early
loss in BMD and often occurred even with preserved visual
acuity. Disease duration was significantly correlated with psy-
chophysical deterioration in chromatic and achromatic tasks
but not with mfERG measures. Interestingly, partial correlation
analysis revealed a significant independent correlation with our
CS measures.
CONCLUSIONS. Novel topographic achromatic and chromatic CS
methods can detect and quantify functional impairment in
early stages of BMD, including the involvement of the periph-
eral retina and the central chromatic pathway, and can provide
new pathophysiological information with added value in rela-
tion to electrophysiological and structural measures of damage.
(Invest Ophthalmol Vis Sci. 2008;49:5553–5560) DOI:10.1167/
iovs.08-2093
Best vitelliform macular dystrophy (BMD), also known asvitelliform macular degeneration type 2, is an autosomal
dominant disease that affects the central retina and is charac-
terized by typical egg-yolk macular lesions caused by accumu-
lations of lipofuscin within and beneath the retinal pigment
epithelium (RPE).1,2 Atrophy of RPE in the fovea usually affects
the overlying photoreceptors and leads to the impairment of
central visual function. The finding of abnormal EOG results
with normal standard ERG results is a hallmark of BMD, sup-
porting the notion that the primary defect derives from the
RPE. Several reports have shown significant variable clinical
intrafamilial and interfamilial expressivity and expressivity
across the eyes of affected persons.3–5
Mutations in the BMD gene, termed Best1 (formerly VMD2;
MIM 153700) and mapped to 11q13, have been identified in
affected families.6,7 Best1 codes for a 585-amino acid trans-
membrane peptide with a predicted size of 68 kDa, named
bestrophin. Best1 mRNA is expressed mainly in the retina,
especially in the basolateral plasma membrane of retinal pig-
ment epithelial cells.8 In 2002, Sun et al.9 demonstrated that
the bestrophin homologs are oligomeric chloride channels
sensitive to intracellular calcium. However, no evidence for
direct involvement of bestrophin in the generation of light
peak was found by Marmorstein et al.10 in 2004.
The pathophysiology of BMD is not yet clear, and it may
well be necessary to revisit the hypothesis that photoreceptor
damage may occur even earlier in the natural history of the
disease than previously believed. Indeed, in donor eyes from
BMD patients, retinal pigment epithelial and foveal photore-
ceptor loss was observed.11 In 1982, Frangieh et al.12 found
fine granular deposits in degenerating photoreceptors and in
Mu¨ller cells, providing further evidence that the neural retina is
an important locus of damage.
Recent findings have indeed shown that cone function is
impaired in the very early stage of the disease; hence, it cannot
be excluded that a disease mechanism operates early at the
photoreceptor level. Abnormal flicker fusion threshold inten-
sities and chromatic dysfunction have been observed in BMD
patients with normal and near-normal Snellen visual acuity.13,14
Furthermore, L/M-cone driven ERG showed that these two
cone pathways are differentially affected by retinal degenera-
tion.15 Few studies, however, have focused on the quantifica-
tion of spatial retinal impairment in BMD and its correlation
with disease progression and visual acuity (VA). Macular dys-
function was previously assessed by Falsini et al.,16 who re-
corded reduced macular flicker ERGs in patients with early-
stage BMD. We previously demonstrated abnormal foveomac-
ular chromatic contrast sensitivity (CS) along all the three cone
confusion lines in BMD, even when VA was still spared.14 A
recent study has documented reduced multifocal electroreti-
nography (mfERG) amplitudes in BMD, in the centralmost
rings, and in a stage-dependent manner.17
It is important to extend these results using novel spatial
vision phenotyping methods, namely topographic CS measure-
ments that can shed light on peripheral impairment and can
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serve as potential biomarkers to evaluate disease progression.
Accordingly, the present study aimed to evaluate the relevance
of novel spatial achromatic and chromatic CS methods in
phenotyping BMD and their correlation with functional
(mfERG), morphologic (optical coherence tomography [OCT]),
and clinical measures.
METHODS
Characterization of the Clinical Group
Nineteen BMD patients (n  19 eyes; mean age, 31.9 years; range,
10–58 years) from eight families were included in the study and were
compared with an age-similar group of 22 normal-sighted controls (n
22 eyes; mean age, 29 years; range, 9–58 years). Analysis of variance
showed no significant age difference between groups (F-test, P 
0.445).
The diagnosis of BMD was based on the presence of the typical
macular vitelliform lesion assessed by fundus photography, reduced
light-peak to dark-trough ratio of the EOG (Arden ratio lower than 1.8),
and family history (only 3 of 19 had no obvious dominant inheritance
and were, therefore, classified as sporadic). Fundus photographs were
taken according to the guidelines of the Fundus Photograph Reading
Center Department of Ophthalmology and Visual Sciences of the Uni-
versity of Wisconsin. Best-corrected visual acuity was obtained by
postcycloplegic manifest refraction on Snellen charts. No other oph-
thalmologic or systemic condition was present. Clinical data of BMD
patients are shown in Table 1. Disease duration was defined as the
period since decreased VA was first noted and was chosen as a quan-
titative clinical parameter for correlation analyses. One eye per patient
was studied. We chose the eye with best VA (VA  0.2); if both eyes
had similar VA, the right eye was selected for further analysis. Color
vision function was measured with the use of an anomaloscope (model
IF-2; Roland Consult, Wiesbaden, Germany) as the clinical gold stan-
dard and with Rayleigh and Moreland equations and thus was classified
in protanomaly, deutanomaly, and tritanomaly classes.
Informed consent was obtained from all subjects, in strict accor-
dance with the institutional guidelines of our local ethics committee
and after explanation of the objectives and possible consequences of
the study. The research was conducted in accordance with the tenets
of the Declaration of Helsinki.
Contrast Sensitivity Psychophysical Tasks
Achromatic Contrast Sensitivity. CS was assessed indepen-
dently for each random location (one central, four paracentral, four
peripheral; Fig. 1) in an interleaved manner. Grating stimuli (static, 3.5
cpd) were generated from a CRS/VSG 2/5 graphics card (Cambridge
Research Systems [CRS], Rochester, UK), and displayed on a 21-inch
gamma-corrected monitor (frame rate 100 Hz; Trinitron GDM-F520;
Sony, Tokyo, Japan) with a viewing distance of 36 cm and under a
mean background luminance of 51 cd/m2 (Fig. 1).
Luminance contrast or modulation of the stimulus was expressed
according to Michelson: luminance contrast (%)  100  (Lmax 
Lmin)/(Lmax Lmin). An adaptive logarithmic staircase strategy was used
to obtain psychophysical thresholds. Staircases were run for a total of
four reversals, with the contrast at the final two reversals averaged to
estimate the contrast threshold. Results were expressed in terms of
decibel (dB) units: dB  20  log (1/c), with contrast c measured as a
percentage.
This spatial testing procedure was performed monocularly. Sub-
jects were instructed to fixate a black square (1°  1°) in the center of
the screen and to report the presence of vertical “striped” targets
(detection task) by means of a button press. Stimulus duration was 200
ms, and ISI was jittered between 2300 to 2800 seconds. Participant
reliability was evaluated by the inclusion of false-positive and -negative
“catch trials,” and all results with false-positive and false-negative errors
of 33% or greater were excluded, according to standard criteria.18
Fixation loss was monitored using an eye-tracking methodology (CRS
device) that provided detailed measurements of pupil position. Partic-
ipants with difficulties in fixation were excluded.
For the analyses of the CS in eccentricity, three zones were defined:
zone 0 corresponded to the 5° central visual field, zone 1 contained
locations between 5° and 10o eccentricity, and zone 2 included stimuli
between 10o and 20o eccentricity.
Chromatic Contrast Sensitivity. To evaluate independently
red-green and blue-yellow pathways, we used sinusoidal gratings sim-
ilar to the achromatic stimulus (static, 3.5 cpd) modulated along lines











I 1 M 36 16 20 0.8 0.8 Normal
2 F 10 8 2 0.8 0.8 Normal
II 3 M 51 16 35 1.0 1.0 P  T
4 M 19 6 13 1.0 0.9 T
III 5 M 37 25 12 1.0 0.1 P
6 M 35 23 12 0.2 0.2 P  T
IV 7 M 14 6 8 0.2 0.8 P  T
8 M 53 22 31 0.8 0.8 P  T
9 F 25 18 8 0.8 0.8 P  T
V 10 M 58 40 18 0.8 0.6 T
VI 11 M 42 33 9 1.0 1.0 T
VII 12 F 44 10 34 0.4 0.3 P  T
13 M 20 5 15 1.0 1.0 T
14 M 14 6 8 1.0 0.2 P  T
15 M 20 5 15 0.2 0.4 T
16 M 45 10 35 0.3 0.9 P  T
17 F 27 26 1 0.8 1.0 P  T
18 M 36 15 21 0.4 0.8 P  T
VIII 19 F 14 11 3 0.3 0.1 ND
Age, onset (age at the first detected clinical manifestation), disease duration and best-corrected visual
acuities for right (OD) and left (OS) eyes are indicated. Color vision function was measured using an
anomaloscope and was classified according to protanomaly (P), deutanomaly (D), and tritanomaly (T). ND,
not determined.
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in color space close the three main confusion axes within the Com-
mission International d’Eclairage (CIE) 1931 x,y space14,19 but with
slight offsets from the isoluminant plane to ensure similar computed
quantal catches across tasks. This allowed for comparison with our
own previous study,14 in which isoluminance was prioritized over
quantal catch equivalence. We used the same setup for stimuli gener-
ation and monitor calibration, staircase procedure, viewing distance,
subject instructions, and performance reliability as defined for the
achromatic CS tests, which ensured test comparability.
We measured chromatic contrast thresholds in five locations within
10° of visual field (a central circular test field subtending 2° of visual
angle, zone 0; and four 5°–10° testing locations, zone 1; displayed as
shown in Fig. 2). Psychophysical chromatic sensitivity was tested in a
randomly interleaved manner for each contrast axis. The red-green
pathway was tested with two distinct procedures by modulating con-
trast close to the protan and deutan axes (averages across these two
were used as an estimate of red-green CS). Staircase vector extreme
coordinates in the CIE 1931 x,y color space were as follows: protan,
x  0.433, y  0.295; deutan, x  0.371, y  0.243. The blue-yellow
stimulus was modulated close to the tritan axis (extreme CIE 1931 x,y
chromaticity coordinate x  0.254, y  0.197). The white starting
point was x  0.306, y  0.314. Mean background luminance and
stimulus luminance were set equally to 22.20, 41.50, and 6.75 cd/m2
for protan, deutan, and tritan axes, respectively, to obtain nearly
identical average cone quantal catches at 2° and 10° (9.79  0.64 [SD]
log quanta  s1  cone1 for 2° stimulus and 9.82  0.66 [SD] log
quanta  s1  cone1 for 10°). Therefore, chromatic pathways20,21
could be compared at approximately the same adapting level. The
effective quantal catch produced in each cone by each primary was
calculated by multiplying the Stockman and Sharpe cone fundamentals
for 2° or 10° with the emission spectra of the three phosphors and a
constant, k, and by integrating the product over wavelength.22,23 The
constant, k, is different for each cone, depending on the product of the
ocular media transmittance and the absolute absorption coefficients for
the wavelength of the maximal absorption probability for each cone.
The emission spectra of the red, green, and blue phosphors of the
monitor were measured separately in steps of 1 nm with a calibrated
spectroradiometer (CRS SpectroCAL, Rochester, UK).
Electrophysiological Recordings
We recorded mfERGs using DTL fiber electrodes, after a light adapta-
tion period of 10 minutes and pupil dilation with tropicamide, before
fundus photography, with a commercial system (RETIscan System;
Roland Consult).24 Refractive errors were corrected in relation to the
viewing distance. The stimulus used in the mfERG consisted of 61
hexagons covering a visual field of up to 30° and presented on a
20-inch monitor at a viewing distance of 33 cm. Luminance was 120
cd/m2 for white hexagons and approximately 1 cd/m2 for black hexa-
gons, resulting in a Michelson contrast of 99%. The hexagonal areas
increased with eccentricity to compensate for local differences in
signal amplitude because of differences in cone density across the
retina (leading to a fourfold change in hexagon area size). Each hexa-
gon was temporally modulated between light and dark according to a
binary m-sequence (frame rate, 60 Hz). Observers were instructed to
fixate a small black cross in the center of the stimulus. Fixation was
continuously checked by means of online video-monitoring during the
approximately 8-minute recording sessions. To improve fixation stabil-
ity, sessions were broken into 47-second segments; eight trials were
recorded in total. Signals were amplified with a gain of 100,000 and
were band-pass filtered (5–300 Hz).
Reference and ground electrodes were attached to the ipsilateral
outer canthus and forehead, respectively. The surface electrode im-
FIGURE 1. Tested locations and stim-
ulus layout for the achromatic CS
test. CS was assessed independently
and in an interleaved manner for
each of the nine locations tested.
FIGURE 2. Tested locations and stim-
ulus layout for the chromatic CS test
(A) and the CIE 1931 x,y chromatic-
ity diagram showing the white, pro-
tan, deutan, and tritan points (B).
Note that luminance was manipu-
lated such that cone quantal catches
remained constant. CS obtained for
each of the three color axes tested
was expressed in decibels.
IOVS, December 2008, Vol. 49, No. 12 Retinal Function in Best Macular Dystrophy 5555
pedance was less than 10 k. Analyses were performed with the
system software (RETIscan; Roland Consult) and standard statistical
packages. First-order kernels were used for mfERG analysis because of
their close correlation with the function of the outer retina.25 The
obtained local ERGs responses were normalized by the area of stimulus
delivery to obtain a density response (nv/deg2). For each hexagon, the
peak amplitude of P1—defined as the difference between N1 and P1
amplitudes—the N1 peak, and the implicit time of P1 component were
computed. To easily evaluate spatial differences of the local ERG
responses, responses from the 61 elements were divided into averages
of five concentric rings around the fovea.
Optical Coherence Tomography
We used an OCT device (Stratus OCT; Carl Zeiss Meditec, Dublin, CA)
to obtain cross-sectional images centered in the macula,26 with axial
resolution of 10 m or less, transversal resolution of 20 m, and
longitudinal scan range of 2 mm. With this OCT device (Stratus OCT;
Carl Zeiss Meditec), six radial line scans 6 mm in length and 128
A-scans 30° apart were scanned in 1.92 seconds, and a nine-region
retinal thickness map was obtained by segmenting the retina from
other layers with an algorithm detecting the edge of the RPE and the
photoreceptor layer.
Macular retinal thickness was calculated by computing the distance
between the signal from the vitreoretinal interface and the signal from
the anterior boundary of the RPE. Retinal thickness was presented as a
nine-region thickness map showing the interpolated thickness for each
area, with a central circle of 500 m radius (ring 0) and two outer
circles with radii of 1500 m (ring 1) and 3000 m (ring 2). The
interpolated thickness was displayed using a false color scale, in which
bright colors (red and white) corresponded to thickened areas and
darker colors (blue and black) were assigned to thinner areas.
Statistical Analysis
We performed analysis of variance (ANOVA), with post hoc Fisher
protected least significant difference (PLSD) correction using statistical
software (StatView; Abacus Concepts, Berkeley, CA). Results with P 
0.05 were considered statistically significant. Correlation analyses were
performed using Fisher-to-Z transformation of Pearson coefficients. In
cases of ranked variables, such as disease stage, correlation analyses
were computed using the Spearman coefficient.
RESULTS
Achromatic Contrast Sensitivity
Representative maps of achromatic CS from BMD and control
participants whose performance was close to their group me-
dian are illustrated in Figure 3A. These CS maps demonstrate
significant impairment of spatial CS in BMD (Fig. 3B; P 
0.0001 for the global grand average of CS; ANOVA). Compar-
ison of CS across three eccentricity zones showed, as ex-
pected, higher CS for central locations (zone 0) and locations
up to 10° (zone 1) compared with the more peripheral tested
locations (zone 2), in the aged-matched control group. This
was also true for the BMD group. Further analysis confirmed
the hypothesis that deterioration of CS function in BMD is not
specifically confined to the centralmost regions of the visual
field. Indeed, we have found significant impairment at all
tested eccentricities (P  0.0012, P  0.0001, and P  0.0001
for zone 0, zone 1, and zone 2, respectively; Fisher PLSD).
Considering individual data, we found that only 3 of the 19
affected eyes exhibited CS above the lower fifth percentile of
the control group, corresponding to eyes with VA of 0.8 or
better and with less than 9 years of disease progression.
We performed correlation analyses between CS and clinical
measures to better understand patterns of disease progression.
We found a significant correlation between the global grand
average CS and disease stage (Rho correlation coefficient [r] 
0.504; P  0.027). Additional correlation analyses were un-
dertaken to find the spatial source that best explained these
results and revealed that this pattern was significant for the
central regions, in contrast with the more peripheral locations
(r  0.507, P  0.025 for zone 0; r  0.517, P  0.022 for
zone 1; and r  0.378, P  0.111 for zone 2). Interestingly,
when we analyzed disease progression in terms of disease
duration, an opposite spatial relation was observed, with sig-
nificant correlations achieved in the more peripheral retina
(Fig. 3C; r  0.219, P  0.373 for zone 0; r  0.246, P 
0.280; r  0.534, P  0.017). These effects suggest that the
impairment of CS in peripheral regions is clinically useful.
Accordingly, CS measures obtained from more peripheral re-
gions of the retina are potentially useful to monitor disease
progression and duration. No significant correlation was found
with VA (except, as expected for zone 0, r  0.472 and P 
0.040), further proving the dissociation with central visual
function and the importance of other functional measures to
evaluate disease progression.
FIGURE 3. Achromatic CS function (ACS) in BMD patients. (A) Maps
of ACS from representative BMD patients and control subjects. (B) Box
plots of CS from the three different eccentricity tested regions. (C)
Correlation of CS at 10° to 20° regions (zone 2) with disease duration.
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Chromatic Contrast Sensitivity
We determined the CS for red-green and blue-yellow chromatic
pathways in BMD patients and control subjects. In patient and
control groups, higher average CS was observed for the red-
green than for the blue-yellow pathways (P  0.033 and P 
0.0001 for BMD patients and control subjects, respectively; Fig.
4A). Spatial disease-related dissociation in CS was again found,
but with an opposite bias compared with the achromatic task
and more evident central impairment. If only global measures
were to be considered, significant differences between BMD
patients and control subjects were found for grand average
chromatic CS (P 0.044) but not for each chromatic axis (P
0.092 and P  0.155 for blue-yellow and red-green biased
pathways, respectively), suggesting that chromatic deficits are
detected with smaller statistical power when isoquantal
catches are ensured and isoluminance is broken (for an alter-
native approach, see Campos et al.14). When the analysis was
performed separately for each test zone (0 and 1), we observed
an overall impairment of chromatic function in BMD patients
in the most central zone for both tests (Fig. 4B; zone 0, P 
0.011; zone 1, P  0.293). However, post hoc analyses re-
vealed that this effect was contributed primarily from impair-
ment in the blue-yellow test (zone 0; P 0.013). No significant
dysfunction of chromatic CS function was found for the more
peripheral locations in BMD patients (zone 1). These results
suggest significant chromatic impairment (in agreement with
our own previous study14), albeit with higher statistical power
under isoluminant conditions compared with quantal catch
equivalence.
For chromatic pathways, reductions of CS in BMD patients
showed strong and significant correlations with disease pro-
gression, as assessed by analysis of the roles of disease duration
and stage, as shown in Figure 4C (disease duration: r 
0.691, P  0.002, for red-green performance measures; r 
0.562, P  0.022, for blue-yellow performance measures).
When considering correlation of chromatic CS with disease
stage, we found a pattern of significant correlations for the
centralmost areas (zone 0: Rho r  0.553, P  0.025 for
red-green axes; and Rho r  0.597, P  0.017 for the
blue-yellow pathway) but not for the more peripheral retina
locations (zone 1: r  0.351, P  0.186 for the red-green
axes and r  0.216, P  0.295 for the blue-yellow pathway).
No significant correlations were found between visual acuity
and impairment in any of the chromatic CS tests (r  0.456
and P  0.068 for red-green axes; r  0.375 and P  0.134
for blue-yellow pathway; Spearman correlation coefficients).
Electrophysiological Observations. mfERGs of a control
subject and a BMD patient are shown in Figure 5A. There was
a substantial reduction in mfERG amplitude responses in BMD
patients when compared with controls (Fig. 5B; P 0.0001 for
both N1 and P1 components). With regard to the N1 and P1
mfERG components, amplitudes were found to be dramatically
reduced for all rings in BMD patients (mfERG responses for N1
amplitude rings 1–3 and 5 and for P1 amplitude rings 1–5, P 
0.005; for N1 amplitude ring 4, P  0.178). Abnormal mfERG
responses were found for all tested eccentricities, though ef-
fect size was clearly smaller for more peripheral rings.
No significant differences in implicit times were found for
P1 peak time response between the two groups, for any of the
eccentricity rings (Fig. 5C). No correlation was found between
N1 or P1 peak amplitude and disease duration. Disease pro-
gression (duration and stage), however, was significantly cor-
related with P1 implicit time (Fig. 5D; disease duration r 
0.212, P  0.007; disease stage r  0.407, P  0.0001);
therefore, delayed mfERGs responses may well appear in later
stages of the disease. P1 grand average mfERG responses were
highly correlated with CS measures (r  0.491, P  0.037 for
the global CS-P1 sum correlation), especially for the more
central retina locations (zone 0: r  0.508, P  0.030; zone 1:
r  0.490, P  0.038) but not for the most peripheral area
(zone 2: r  0.262, P  0.299). P1 amplitudes at ring 1 were
also significantly correlated with global CS measures (r 
0.514, P  0.028). Partial correlation analyses proved that the
correlations of mfERG measures with CS function were inde-
pendent of the correlations of the latter, with clinical parame-
ters such as disease duration and visual acuity.
Morphologic Measures Obtained Using OCT and Cor-
relation with Psychophysical Performance. OCT images
acquired through the fovea showed three major patterns of
retinal histopathology (Fig. 6): pattern A, relatively preserved
central foveal depression and mild thickness increase of the
retina; pattern B, severe thinning of neurosensory retina at the
fovea and moderate elevation of the retina; pattern C, severe
thinning of neurosensory retina at the fovea and cystic macular
changes in the outer retinal layers that can vary in size and
number and that eventually span nearly the entire thickness of
the retina. Five of 19 (26%) eyes studied shared pattern A, had
a mean central foveal thickness (ring 0) of 255  20 m, and
FIGURE 4. Chromatic CS function in BMD patients. (A) Bar plot of
blue-yellow and red-green chromatic CS in BMD patients and control
subjects. (B) Box plots of chromatic CS sorted across central (zone 0)
and peripheral (zone 1) test locations. (C) Correlation of chromatic CS
across distinct color pathways with disease duration and disease stage.
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were characterized by a typically preserved VA (mean VA,
0.91) and short disease duration (mean, 11.9 years). Pattern B
was found in 3 of 19 (16%) eyes with significantly reduced
mean VA (mean VA, 0.67; P  0.0001) and longer disease
duration (mean, 14.3 years; P 0.587) than those of pattern A.
In pattern C, where serous retinal detachment was observed,
the mean VA was 0.80, and retinal thickness was significantly
higher for the two central rings than in pattern B (P 0.011 for
the central ring and P  0.043 for the after ring). The longest
disease duration was observed in pattern C (20.8 years; P 
0.024). Therefore, with disease progression, histologic profiles
of BMD evolved from pattern A to pattern B, which turned out
to be highly correlated with VA loss. Later, cystic macular
changes varying in size and number may appear; this pattern
was more prevalent with long-term disease progression.
When morphologic evaluation obtained by OCT was corre-
lated with measures of retinal function, we did observe that
evolution from pattern A to pattern B is characterized by a
significant global chromatic CS dysfunction (P 0.012). Thick-
ness of the neurosensory retina in ring 1 was significantly
correlated with functional parameters such as P1 amplitude
and with chromatic and achromatic CS measures (P1 ampli-
tude of ring 1, r  0.562, P  0.014; chromatic CS measures,
r  0.357, P  0.037; achromatic global CS, r  0.507, P 
0.044). Interestingly, retinal thickness at ring 1, a region char-
acterized by a high density of photoreceptor cells, also showed
a strong correlation with VA (r 0.149, P 0.012) and disease
duration (r  0.242, P  0.047).
DISCUSSION
The present study provides new insights into structure-func-
tion correlations at the level of the neurosensory retina in
BMD, including the involvement of the central and peripheral
cone pathways, achromatic channels in vision, and their rela-
tionship with clinical markers of disease progression.
FIGURE 5. (A) mfERGs obtained from
representative BMD patients and
control subjects. Plots of the 61 hex-
agonal responses are presented. For
each hexagonal response, the hexa-
gon number (above the local ERG)
and the respective P1 amplitude (be-
low the local ERG) are indicated.
Three-dimensional plots of P1 ampli-
tudes obtained by mfERG clearly
show higher amplitudes on the cen-
tral hexagons than in the peripheral
tested locations. (B) Statistical analy-
ses of mfERG peak amplitudes are
shown. P1 and N1 amplitudes were
significantly reduced in BMD for dif-
ferent eccentricity rings up to 30°.
(C) P1 peak time was not signifi-
cantly altered between patients and
controls for any of the rings exam-
ined. (D) Correlation of P1 peak time
with disease progression (disease
stage and duration).
5558 Maia-Lopes et al. IOVS, December 2008, Vol. 49, No. 12
Accordingly, our work confirmed that BMD patients have
neurosensory retina dysfunction up to 30°, as shown by re-
duced mfERG peak amplitudes and impaired peripheral achro-
matic CS. This functional impairment, which, according to
Hood,27 can be speculated to be attributed to either cone
photoreceptor cell loss or damage to the cone outer segments,
was more extensive in our population sample than has been
found by others.17,28–30 One explanation for this largely de-
creased mfERG response may be the larger number of affected
eyes tested in the present study, which increases statistical
power. On the other hand, this significantly reduced response
in the periphery was also detected in adult-onset vitelliform
macular dystrophy (AVMD), which has been suggested to have
a considerable etiological overlap with Best disease.31,32 Our
hypothesis that there is a pan-retinal defect in BMD is corrob-
orated by the recently reported abundant expression of (mu-
tated) bestrophin in the peripheral retina and of global retinal
pigment epithelial failure (as obtained by the commonly al-
tered EOG measures).1–3,33–35 We do believe that the exten-
sion of retinal damage and the familial intravariability and
intervariability of age of onset and range of visual loss are part
of a scenario of variable expression in BMD.36,37 Accordingly,
for this autosomal recessive macular disease, there are reports
of BMD families in whom some patients and generations are
asymptomatic.38,39 Thus, we speculate that the overlap be-
tween BMD and AVMD might be explained by the low pen-
etrance and the great variability of disease symptoms in these
vitelliform macular diseases.
The use of a new and comprehensive quantitative method-
ology to phenotype BMD provided interesting patterns of
structure-function correlations. Morphologic alterations were
functionally accompanied by correlated decreases in mfERG
responses and reduced achromatic CS function with peripheral
predominance. Furthermore, central deficits in the chromatic
CS function were also typical as early indicators of functional
damage, extending our previous work14 showing that macular
S-cone dysfunction can be found at least as early as protan and
deutan deficits. The accumulation of “yellow” pigment in BMD
may partly influence the sensitivity of the blue cone pathway in
the central region, though subjects may still use preserved
macular regions to perform the color discrimination task. Rod
intrusion is probably not a main contributor to the phenotype
given that there are few rods in the central retina.
Our previous study14 emphasized the detection of color-
contrast deficits at isoluminance, whereas the present study
emphasized similar quantal catches. It appears that the former
approach may be more sensitive to detect dysfunction in chro-
matic pathways. Disease progression (as assessed by duration
after the onset of initial clinical manifestations) was character-
ized by OCT-documented changes of the histologic integrity of
the retina. Moreover, disease progression was also correlated
with impairment of the CS function, particularly in more pe-
ripheral regions of the retina. The amplitudes of mfERG re-
sponses were found to be dramatically reduced in all subjects.
Part of the variance of these measures was highly correlated
with CS performance, suggesting that mfERG and achromatic
CS can be useful independent tools to evaluate early functional
loss in members of families with suspected disease. It is impor-
tant to emphasize that the robust central mfERG responses
were obtained from BMD patients with relatively preserved
VA.
Our study shows that cross-correlation analysis of electro-
physiological, psychophysical, and morphometric data im-
prove quantitative phenotyping in BMD. All our quantitative
parameters showed significant correlations with clinical, psy-
chophysical, and electrophysiological data. Furthermore, we
suggest that achromatic CS and mfERG measures are especially
important for detecting peripheral visual impairment early in
families with a positive history of BMD. On the other hand,
damage assessment in chromatic pathways, OCT morphologic
evaluation, and central achromatic CS functions represent suit-
able approaches to study macular function and to complement
the evaluation of damage and disease progression in BMD.
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